TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Clinical trial NCT07223203 · RECRUITING
Trial details
- NCT number
- NCT07223203
- Sponsor
- Alnylam Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-12
- Primary completion
- 2027-12-27
- Enrollment
- 125
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.